{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:14:56Z","timestamp":1790399696183,"version":"4.1.0"},"reference-count":24,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2013,3,7]],"date-time":"2013-03-07T00:00:00Z","timestamp":1362614400000},"content-version":"vor","delay-in-days":1892,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2008,1]]},"abstract":"<jats:p>The systemic exposure of fluticasone propionate with hydrofluoroalkane propellant compared with chlorofluorocarbon propellant and the effect of fluticasone propionate hydrofluoroalkane on 24\u2010hour urinary cortisol in children aged 4 to 11 years with asthma were evaluated. Study 1 was an open\u2010label, 2\u2010way crossover study in which 16 subjects were randomized to 7.5 days each of fluticasone propionate hydrofluoroalkane 88 \u03bcg twice a day or fluticasone propionate chlorofluorocarbon 88 \u03bcg twice a day. In study 2, 63 subjects received 13.5 days of placebo followed by 27.5 days of fluticasone propionate hydrofluoroalkane 88 \u03bcg twice a day. The main outcome measure for study 1 was the difference between fluticasone propionate hydrofluoroalkane and fluticasone propionate chlorofluorocarbon in fluticasone propionate AUC<jats:sub>last<\/jats:sub> (area under the plasma fluticasone propionate concentration\u2013time curve from zero up to the last quantifiable plasma concentration), and for study 2, 24\u2010hour overnight urinary cortisol excretion. In study 1, fluticasone propionate systemic exposure was significantly lower (55%) with hydrofluoroalkane metered dose inhaler compared with chlorofluorocarbon metered dose inhaler. Study 2 showed no statistically significant changes in 24\u2010hour overnight urinary cortisol excretion and no relationship to fluticasone propionate systemic exposure at this dose. The results of these 2 studies showed that in children aged 4 to 11 years with asthma, fluticasone propionate hydrofluoroalkane has lower systemic exposure compared with chlorofluorocarbon and no hypothalamic\u2013pituitary\u2013adrenal axis effects as measured by 24\u2010hour urinary cortisol excretion.<\/jats:p>","DOI":"10.1177\/0091270007309704","type":"journal-article","created":{"date-parts":[[2007,12,19]],"date-time":"2007-12-19T21:23:16Z","timestamp":1198099396000},"page":"108-116","source":"Crossref","is-referenced-by-count":3,"title":["Systemic Exposure and Urinary Cortisol Effects of Fluticasone Propionate Formulated With Hydrofluoroalkane in 4\u2010 to 11\u2010Year\u2010Olds With Asthma"],"prefix":"10.1002","volume":"48","author":[{"given":"Kennet T.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Milgrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. Kellie","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arde L.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Matz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michae J.","family":"Welch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Cahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davi A.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Kathman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng\u2010Fang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rober L.","family":"Kunka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,7]]},"reference":[{"key":"e_1_2_6_2_2","unstructured":"BloomB DeyAN.Summary health statistics for U.S. children: National Health Interview Survey 2004.Vital Health Stat 10.2006 No 227.http:\/\/www.cdc.gov\/nchs\/data\/series\/sr_10\/sr10_227.pdf. Accessed May 11 2007."},{"key":"e_1_2_6_3_2","volume-title":"Executive Summary of the NAEPP Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma: Update on Selected Topics 2002 (NIH publication 02\u20135075)","author":"National Asthma Education and Prevention Program","year":"2002"},{"key":"e_1_2_6_4_2","first-page":"3","volume-title":"Clinical Practice Guidelines of the American Academy of Pediatrics: A Compilation of Evidence\u2010Based Guidelines for Pediatric Practice","author":"Practical guideline for the diagnosis and management of asthma","year":"1999"},{"key":"e_1_2_6_5_2","volume-title":"Pocket Guide for Asthma Management and Prevention. Based on the Workshop Report: Global Strategy for Asthma Management and Prevention (NIH publication 02\u20133659)","author":"Global Initiative for Asthma","year":"2002"},{"key":"e_1_2_6_6_2","volume-title":"Flovent (fluticasone propionate) [package insert]","year":"2007"},{"key":"e_1_2_6_7_2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1155\/2003\/627531","article-title":"Fluticasone propionate 100 m\u0308g BID using a non\u2010CFC propellant, HFA 134a, in asthmatic children","volume":"10","author":"Lyttle B","year":"2003","journal-title":"Can Respir J."},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200121100-00004"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(00)80149-3"},{"key":"e_1_2_6_10_2","first-page":"S29","article-title":"Clinical efficacy and safety of fluticasone propionate 250 mcg twice daily administered via a HFA\u2010134a pressurized metered dose inhaler to patients with mild to moderate asthma","volume":"94","author":"Tonnel AB","year":"2000","journal-title":"Respir Med."},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(00)80148-1"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1211\/0022357991776967"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(99)70016-3"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(00)80144-4"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/136.1.225"},{"key":"e_1_2_6_16_2","volume-title":"Pulmonary Function Testing in Children: Techniques and Standards","author":"Polgar G","year":"1971"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(98)00374-0"},{"key":"e_1_2_6_18_2","first-page":"212","article-title":"Fluticasone plasma concentrations in children with asthma after delivery by MDI","volume":"6","author":"Bessmertny O","year":"2001","journal-title":"J Pediatr Pharmacol Ther."},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)61190-8"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2003.12.409"},{"issue":"30","key":"e_1_2_6_21_2","first-page":"341S","article-title":"The pharmaceutical evaluation of the new HFA\u2010134a metered dose inhaler (MDI) formulations of fluticasone propionate","volume":"14","author":"Boles MG","year":"1999","journal-title":"Eur Respir J."},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(00)80143-2"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.98.12061346"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1089\/pai.2006.19.106"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(98)70052-1"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270007309704","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/0091270007309704","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T08:20:45Z","timestamp":1697098845000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/0091270007309704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["10.1177\/0091270007309704"],"URL":"https:\/\/doi.org\/10.1177\/0091270007309704","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}